Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.
You may also be interested in...
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.
Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
Top-line results from the Phase III ARISTOTLE trial show the novel anticoagulant was superior to warfarin on safety and efficacy - a pleasant surprise for investors.